R. Bradley Gray has served as a member of the board of directors and as President and Chief Executive Officer since June 2010. Prior to joining our company, Mr. Gray held various positions at Genzyme, a biotechnology company acquired by Sanofi in 2011. He served as Vice President of Product & Business Development for Genzyme Genetics, the diagnostic services division of Genzyme, from June 2008 to May 2010, leading the development of molecular diagnostics and partnering activities. From September 2006 to June 2008, he served as Vice President of Business & Strategic Development for Genzyme Genetics, leading growth efforts through partnerships and licensing. Mr. Gray joined Genzyme in October 2004 as Director of Corporate Development, supporting business development and leading Genzyme Ventures, the corporate venture capital fund of Genzyme. Prior to joining Genzyme, Mr. Gray was a management consultant in the healthcare practice of McKinsey & Company, a global management consulting firm, from September 2000 to October 2004, where he worked with senior healthcare executives in the United States and Europe on a broad range of issues including pharmaceutical and diagnostic product strategy, post-merger integration, organization design, and operational turnarounds. Mr. Gray received a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.
Joseph M. Beechem Ph.D. Senior Vice President of Research and Development
Joseph M. Beechem, Ph.D. has served as Senior Vice President of Research and Development, since April 2012. Prior to joining our company, Dr. Beechem held various positions at Life Technologies, a publicly-traded biotechnology tools company, most recently as Vice President, Head of Advanced Sequencing and Head of Global Sequencing Chemistry, Biochemistry and Biophysics from January 2010 to April 2012. From December 2007 to December 2012, he served as Chief Technology Officer of Life Technologies. During his career at Life Technologies, he led the design and development of multiple genetic analysis technologies, the latest advanced SOLiD sequencing technology and the single molecule nano-DNA sequencing technology. Prior to joining Life Technologies, Dr. Beechem was Chief Scientific Officer at Invitrogen, a publicly-traded biotechnology company that acquired Applied Biosystems in November 2008 to form Life Technologies, from August 2003 to December 2007 and Director of Biosciences at Molecular Probes, a biotechnology company acquired by Invitrogen in 2003, from August 2000 to August 2003. Prior to his industry experience, Dr. Beechem led an NIH-funded research laboratory for 11 years as a tenured associate professor at Vanderbilt University. He has authored or co-authored more than 100 peer-reviewed papers in diverse fields such as biomathematics, physics, chemistry, physiology, spectroscopy, diagnostics and biology. Dr. Beechem is also named on nearly 30 U.S. patents or patent applications and has served on a number of editorial and scientific advisory boards. He received a B.S. in Chemistry and Biology from Northern Kentucky University and a Ph.D. in Biophysics from The Johns Hopkins University.
Wayne Burns Senior Vice President, Operations & Administration
Wayne Burns has served as Senior Vice President, Operations and Administration since October 2012 and served as Chief Financial Officer from April 2007 to September 2012. During the period from March 2009 through June 2010, Mr. Burns served as Acting Chief Executive Officer as well as Chief Financial Officer. Prior to joining our company, Mr. Burns served as Chief Operating Officer and Chief Financial Officer at Action Engine, a developer of a mobile application platform, from 2001 to 2006. From 2000 to 2001, Mr. Burns was a founder and the Chief Executive Officer of SafariDog, a developer of a search engine optimization platform. Mr. Burns also served as Vice President Operations and Chief Financial Officer of NetPodium during 1999 prior to its acquisition by InterVU, where from 1999 to 2000 Mr. Burns served as Vice President of Business Development. During the period from 1990 to 1996, Mr. Burns served as Chief Financial Officer and Vice President of Finance for three venture-backed companies, all of which were acquired by public companies. Mr. Burns spent five years with PricewaterhouseCoopers in the United States and Italy. Mr. Burns received a B.A. in Business Administration with a concentration in Accounting from the University of Washington.
Alessandra Cesano, M.D., Ph.D. Chief Medical Officer
Alessandra Cesano, M.D., Ph.D. has served as Chief Medical Officer since July 2015. Prior to joining our company, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. From 2008 to 2014, she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R&D groups, while providing the overall clinical vision for the organization. In addition, Dr. Cesano has held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Dr. Cesano spent 12 years researching tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center at the University of Pennsylvania. She also holds membership in several professional and scientific societies, and has been an author on over 100 research publications. Dr. Cesano received an M.D., a Board Certification in Oncology and a Ph.D. in Tumor Immunology from the University of Turin. She holds a B.S. in Science and Economics from Istituto Tecnico Commerciale.
David W. Ghesquiere Senior Vice President, Corporate & Business Development
David W. Ghesquiere has served as Senior Vice President, Corporate & Business Development since November 2013. Prior to joining our company, Mr. Ghesquiere was the founder and managing director of Adrenaline Venture & Advisory LLC, an international advisory firm, from August 2012 to November 2013. Prior to founding Adrenaline Venture & Advisory, Mr. Ghesquiere served as Senior Vice President, Corporate & Business Development at Dendreon Corporation, a biotechnology company, from 2011 to 2012. From 2005 to 2010, Mr. Ghesquiere held a variety of executive positions at OSI Pharmaceuticals, acquired by Astellas Pharma in 2010, including Senior Vice-President of Corporate & Business Development and Managing Director of OSI Investment Holdings GmbH and OSI Investment Management GmbH, OSI's wholly owned, Switzerland-based subsidiaries, where he played a key role in establishing OSI's venture capital arm. Earlier in his career, Mr. Ghesquiere served as Director of Global Business Development for Aventis Pharmaceuticals, which was acquired by Sanofi in 2004, and worked in product marketing at Johnson & Johnson. Mr. Ghesquiere received an M.B.A. from The University of Western Ontario's Ivey School of Business and a B.A. in Economics from The University of Western Ontario.
James A. Johnson Chief Financial Officer
James A. Johnson has served as Chief Financial Officer since October 2012. Prior to joining our company, Mr. Johnson was Chief Financial Officer of Relypsa, Inc., a privately-held clinical-stage biopharmaceutical company, from May 2011 to September 2012. From September 2009 to October 2010, Mr. Johnson served as Executive Vice President, Chief Financial Officer, Treasurer and Secretary of ZymoGenetics, Inc., a biopharmaceutical company acquired by Bristol-Myers Squibb in October 2010. Mr. Johnson served as ZymoGenetics’ Executive Vice President, Chief Financial Officer and Treasurer from July 2007 to September 2009 and as ZymoGenetics’ Senior Vice President, Chief Financial Officer and Treasurer from February 2001 to July 2007. Mr. Johnson served as Chief Financial Officer, Treasurer and Secretary of Targeted Genetics Corporation, a biotechnology company, from 1994 to February 2001, as its Senior Vice President, Finance and Administration, from January 1999 to February 2001, and as its Vice President, Finance, from 1994 to January 1999. From 1990 to 1994, Mr. Johnson served as Vice President, Finance, and, from 1988 to 1990, as Director of Finance, at Immunex Corporation, a biopharmaceutical company. Mr. Johnson received a B.A. in Business Administration from the University of Washington.
Barney Saunders Ph.D. Senior Vice President of Sales & Marketing
Barney Saunders, Ph.D. has served as Senior Vice President of Sales & Marketing since March 2015, and previously served as our Senior Vice President & General Manager, Life Sciences from September 2012 to March 2015 and our Chief Commercial Officer September 2010 to September 2012. Prior to joining our company, Dr. Saunders served as Chief Commercial Officer of Microchip Biotechnologies (now IntegenX), a manufacturer of automation systems enabling microsample preparation and analysis for the life sciences, from September 2005 to June 2010. Prior to joining Microchip Biotechnologies, Dr. Saunders served as General Manager at Agilent Technologies, a publicly-traded measurement company providing core bio-analytical and electronic measurement solutions, from 2000 to 2004, where he led the team that launched the first commercially-available, complete genome arrays for human, rat and mouse and also entered the array CGH (comparative genomic hybridization) market. Dr. Saunders began his career with Amersham International, a pharmaceutical company specializing in Diagnostics and Life Sciences which was acquired by General Electric in 2004, where he held a variety of commercial positions, of increasing responsibility, in the United States and Europe from 1988 to 2000. Dr. Saunders received a B.Sc. Hons in Biological Sciences and Ph.D. in Rice Resistance Gene Expression from Birmingham University, England.
Mary Tedd Allen Ph.D. Vice President of Operations
Mary Tedd Allen, Ph.D. transitioned into her role as Vice President of Operations in early 2016, she previously served as Vice President of Manufacturing. Prior to joining our company, Dr. Allen served as the Director of Research and Programs at the Washington Technology Center, Washington state’s non-profit technology-based economic development enterprise, from February 2006 to February 2007. Before joining the Washington Technology Center, Dr. Allen was Vice President of the Advanced Manufacturing and Development group at Applied Biosystems, a publicly-traded biotechnology company acquired by Invitrogen in November 2008 to form Life Technologies, from February 2002 to August 2005. Dr. Allen has more than 20 years of experience managing product development and manufacturing groups for both semiconductor and biotech applications. She received a B.A. in Chemistry from Mount Holyoke College and a Ph.D. in Chemistry from the University of Rochester.
Doug Farrell Vice President of Investor Relations and Corporate Communications
Doug Farrell has joined NanoString Technologies (NSTG) as Vice President of Investor Relations and Corporate Communications. Mr. Farrell brings 30 years of experience in the Life Sciences industry. Before joining NanoString, Doug was Vice President of Investor Relations and Treasury for 13 years at Affymetrix, a leading provider of tools for genetic research. Doug’s previous experience includes serving as Senior Director of Investor Relations at Aurora Biosciences, which was acquired by Vertex Pharmaceutics, as well as The Liposome Company, which was acquired by Elan Corporation. Prior to joining The Liposome Company, Doug was a Division Manager and Clinical Marketing Specialist at Genentech for 4 years. Doug began his career at Schering Pharmaceuticals where he worked in Sales and Marketing for 3 years. Doug received a B.S. in Business Administration from Northeastern University, with a dual major in International Business and Marketing. He is a graduate of the Corporate Governance Institute at San Diego State University and has been a member of the National Investor Relations Institute since 1998.
Sean Ferree Vice President of Diagnostic Development
Sean Ferree, Ph.D., is the Vice President of Diagnostic Development at NanoString Technologies, where he manages a team of scientists and engineers developing in vitro diagnostics and companion diagnostics for oncology applications. Dr. Ferree led the team that developed the Prosigna Gene Signature Assay as the first decentralized multi-gene expression signature for prognosis in early-stage breast cancer including submitting and defending the test through regulatory clearance in the US and EU. Dr. Ferree has spent the last 10 years in roles of increasing responsibility at NanoString, first developing the research use-only assay, instruments, and software comprising the nCounter Analysis System, then tailoring the platform for use in multiple genomics research applications, and later developing a second-generation system suitable for diagnostic applications. He received his Ph.D. in Chemical Engineering from the University of California, Berkeley and his B.S. in Chemical Engineering from the University of Colorado, Boulder.
Deborah Krogman Vice President of Human Resources
Deborah Krogman brings more than 20 years of HR experience. For the last 8 years she has been the HR leader at HaloSource, a public company with international operations focused around clean water treatment in two separate businesses (commercial, i.e., pool treatment, as well as third world work). Prior to HaloSource, Deborah held various HR roles at Radiant Research and Pathogenisis (now Chiron) as well as at Simpson Investment Company.
Dale R. Levitzke Vice President of Worldwide Sales, Life Sciences and Diagnostics
Dale Levitzke joins NanoString from Illumina, Inc. (NASDAQ:ILMN) where he was Senior Director and Global Sales Manager for the company's PCR and Molecular Biology Division, created following Illumina's acquisition of Helixis in 2010. In that role, he led all aspects of global sales for Illumina's Quantitative Real-Time PCR product line and EpiCentre business, establishing a global distribution network with 38 distributors covering 126 countries. Previously, he headed Global Sales for Helixis, Inc., a developer of advanced nucleic acid analysis tools for research and applied applications. Mr. Levitzke also held the position of General Manager of Corbett Robotics Inc., establishing the direct sales, administrative and service office for Corbett Life Sciences in the United States. Mr. Levitzke began his career as a research scientist and served as a Core Facility Manager at the University of Newcastle’s Analytical and Biomolecular Research Facility. Mr. Levitzke earned a Bachelor of Science with honors in molecular biology at La Trobe University Melbourne.
Jay Seemann Vice President of Global Market Access and Reimbursement
Jay Seemann is the Vice President of Global Market Access and Reimbursement at NanoString Technologies. He is responsible for developing the strategic and tactical execution of the market access and reimbursement commercialization plans for the company’s diagnostic and growing CDx portfolio. He is an established industry executive leader in reimbursement and access for diagnostics, specialty biopharmaceuticals, and market commercialization. His experience includes Market Access organizational structure, integration, and execution with start-up, mid-cap, large pharma, and diagnostic commercial organizations. He has successfully launched numerous products in the industry including a diverse and complex portfolio of diagnostic, physician-administered, and oral oncology products. Jay has held leadership roles with companies such as Sanofi Aventis, Bayer, and Onyx Pharmaceuticals. He received his B.S. in Business, Sales and Marketing from Ball State University.
Kathy Surace-Smith Vice President, General Counsel and Corporate Secretary
Kathryn Surace-Smith has served as Vice President and General Counsel since February 2013. From April 2011 to February 2013, she was a legal consultant to medical technology and global health companies in Seattle, including NanoString from August 2012 to February 2013. From October 2002 to January 2011, she was Vice President, General Counsel and Corporate Secretary of SonoSite Inc., a NASDAQ-listed medical device company specializing in hand carried ultrasound systems. From December 1996 to August 2002, she was Vice President, General Counsel and Corporate Secretary at Metawave Communications, a NASDAQ-listed telecommunications equipment provider, where she was part of the management team that took the company public. Prior to that, Ms. Surace-Smith served as International Counsel for Alcatel Telecom in Paris and as Counsel at the European Bank for Reconstruction and Development in London, where she advised on a variety of cross border transactions. Ms. Surace-Smith began her career in private practice with Gibson, Dunn & Crutcher. She received an A.B. in politics from Princeton University and a J.D. from Columbia University School of Law.